RA patients with symptoms < 1 year, no history of DMARD use, DAS28 ≥ 3.2 and ≥1 RA poor prognostic factor

Recruitment from LTHT rheumatology service to VEDERA study

VEDERA procedures at baseline & specified time points:
- MRI of hand MCPs/wrists
- HRUS of hand MCPs/wrists
- Bone densitometry hands, spine & femoral neck
- Plasma/serum samples
- Targeted synovial tissue biopsy

All VEDERA patients offered recruitment into CADERA study
Baseline Cardiac MRI

Randomisation 1:1

- Group 1: Biologic therapy
  - Etanercept* + Methotrexate
- Group 2: Control
  - Methotrexate TT regimen#

1 year Cardiac MRI
Primary Endpoint~

2 year Cardiac MRI
Exploratory Endpoints